ICI based therapies have been recommended as standard first-line regimens in metastatic or advanced NSCLC patients without oncogenic drivers, as monotherapy or combined with chemotherapy according to PD-L1 expression [7]. This evidence concerns the gene CD274 and non-small cell lung carcinoma.